No Correlation Between Urate Crystal Identification and Cardiovascular Risk

A Danish cohort study examined patients with hyperuricemia and compared outcomes in those proven to have urate crystal deposition (317 patients) and matched 1:1 to patients without urate crystals. Interestingly, of the 80,726, 79,629 did not have uric acid crystal identification.

They found no difference between the two groups with regard to cardiovascular outcomes (hazard ratios = 0.86; 95 % confidence interval (CI) 0.52 - 1.43) or death (hazard ratio 0.74; CI 0.45 - 1.21). Hence, the presence of urate crystal precipitations does not to confer an added cardiovascular risk in hyperuricemic patients.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

[...]

A Role for SGLT2 Inhibition in Gout?

By MedPage Today | 17 Dec 2019

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

[...]

Predicting Inpatient Gout Flares

By Jack Cush, MD | 13 Dec 2019

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

[...]

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

By Olga Petryna, MD | 25 Nov 2019

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

By Olga Petryna, MD | 20 Nov 2019

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

You are here